Immunosuppression — Perioperative Management
Build a medication plan with the transplant, rheumatology or IBD team before elective reconstruction. Balance infection and healing risks against allograft rejection or disease flare. An allograft recipient and a patient having renal autotransplantation are different: autotransplantation alone does not create a requirement for anti-rejection medication.
Record the indication, last dose, dosing interval, graft function, recent rejection/infection, blood counts and relevant drug interactions. Document the route while NPO and who will decide when to restart any deliberately withheld medicine.
Solid Organ Transplant Recipients
In a stable recipient, maintenance calcineurin inhibitors, antimetabolites and required corticosteroids generally continue through surgery. Avoid missed doses; arrange alternative administration with transplant pharmacy when oral absorption is unreliable. Monitor calcineurin-inhibitor troughs and renal function when indicated. Macrolides and azole antifungals can markedly change exposure.[1]
Do not independently stop mycophenolate, tacrolimus or another maintenance agent because a fistula or operation is present. Infection, leukopenia, renal deterioration and recent rejection require individualized transplant-team decisions. Sirolimus-related healing concerns may justify a planned interruption or substitution before major surgery; this is not a universal order to stop every mTOR inhibitor without an alternative regimen.[1]
A single-center retrospective study of 300 kidney recipients associated infection-related reduction at 2–6 months with rejection. This supports caution about timing and confounding; it does not establish a routine mycophenolate-reduction protocol for GU fistula repair.[2]
For adrenal-risk assessment and stress coverage, see Steroids. Required transplant treatment and adrenal replacement should be accounted for together without duplicate dosing.
Biologics: Use the Disease and Operation Context
There is no universal rule to hold every biologic until a GU wound has healed.
| Context | Relevant guidance and limit |
|---|---|
| Crohn's disease undergoing abdominal surgery | ECCO 2024 recommends against routinely stopping anti-TNF therapy, vedolizumab or ustekinumab. Evidence and recommendations vary by agent; this does not establish safety for every newer medicine or operation. |
| Ulcerative colitis undergoing surgery | ECCO 2026 suggests biologics probably need not be stopped, considering the dosing interval and procedure. Evidence is limited, especially for pouch construction and small molecules; JAK inhibitors require their own interruption plan. |
| Inflammatory arthritis undergoing elective hip/knee arthroplasty | ACR/AAHKS 2022 conditionally recommends holding biologics and scheduling surgery after the next dose would be due. If withheld, restart after satisfactory healing and no infection, typically around 14 days. These recommendations concern arthroplasty; transfer to GU reconstruction requires specialist judgment. |
These distinctions prevent applying an orthopedic biologic schedule automatically to Crohn-related bowel/urinary reconstruction. Optimize nutrition, inflammation and infection control without provoking an avoidable flare. Severe SLE and individual small-molecule therapies need their specific specialist plans.[3][4][5]
For Crohn-related fistulas, first define the anatomy and drain sepsis. ECCO's recommendation for preliminary seton drainage concerns complex perianal fistulas; it is not an instruction to pass a seton through an enterovesical or other urinary tract fistula. Coordinate bowel, urinary and pelvic drainage or diversion as appropriate.[3]
Infection, Drainage and Reconstruction
Treat symptomatic infection, drain infected collections and establish reliable urinary drainage. Defer elective definitive repair or prosthetic implantation during uncontrolled infection; urgent source-control procedures should not wait for elective optimization. See Transplant urinary leak for anatomy-specific management.
Colonization alone is not an indication for prolonged antibiotics. IDSA recommends culture-directed treatment of asymptomatic bacteriuria before endoscopic urologic procedures that traumatize mucosa, usually a short perioperative course of 1–2 doses started 30–60 minutes beforehand. Its recommendation for uncomplicated AUS/penile-prosthesis implantation differs: no routine ASB screening/treatment, while standard surgical prophylaxis remains necessary. Active infection and operations entering an infected urinary tract require their own treatment plan.[6]
Choose healthy tissue, drainage and any interposition flap according to the defect, perfusion, radiation, contamination and prior repairs. Immunosuppression alone does not mandate a particular flap or guarantee that adding one prevents recurrence. Coordinate medication changes, nutritional/glucose optimization and postoperative surveillance with the treating team.
References
1. Mukadam M, Irshad Z. Transplant immunosuppression in the perioperative period. Royal College of Surgeons of Edinburgh, 2022. Professional guidance.
2. Yang B, Ye Q, Huang C, Ding X. Impact of infection-related immunosuppressant reduction on kidney transplant outcomes: a retrospective study considering the temporal dynamics of immunosuppressive requirements. Transpl Int. 2023;36:11802. doi:10.3389/ti.2023.11802
3. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohns Colitis. 2024;18:1556–1582. doi:10.1093/ecco-jcc/jjae089
4. Adamina M, Kienle P, Chaparro M, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2026;20:jjag072. doi:10.1093/ecco-jcc/jjag072
5. Goodman SM, Springer BD, Chen AF, et al. 2022 ACR/AAHKS guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res. 2022;74:1399–1408. doi:10.1002/acr.24893
6. Nicolle LE, Gupta K, Bradley SF, et al. IDSA 2019 clinical practice guideline for the management of asymptomatic bacteriuria. Clin Infect Dis. 2019;68:e83–e110. doi:10.1093/cid/ciy1121